000281802 001__ 281802
000281802 005__ 20251112125157.0
000281802 0247_ $$2doi$$a10.1002/alz.70783
000281802 0247_ $$2ISSN$$a1552-5260
000281802 0247_ $$2ISSN$$a1552-5279
000281802 037__ $$aDZNE-2025-01188
000281802 082__ $$a610
000281802 1001_ $$00000-0002-2597-1992$$aBiel, Davina$$b0
000281802 245__ $$aA systematic comparison of ATN biomarkers for monitoring longitudinal cognitive changes in Alzheimer's disease
000281802 260__ $$aHoboken, NJ$$bWiley$$c2025
000281802 3367_ $$2DRIVER$$aarticle
000281802 3367_ $$2DataCite$$aOutput Types/Journal article
000281802 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1762947938_29016
000281802 3367_ $$2BibTeX$$aARTICLE
000281802 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000281802 3367_ $$00$$2EndNote$$aJournal Article
000281802 520__ $$aINTRODUCTIONWith anti-amyloid beta (Aβ) therapies approved for Alzheimer's disease (AD), surrogate biomarkers are needed to monitor clinical treatment efficacy. Therefore, we systematically compared longitudinal changes in A/T/N biomarkers (amyloid-positron emission tomography [PET], tau-PET, plasma phosphorylated tau at threonine 217 [p-tau217], and magnetic resonance imaging) for tracking cognitive changes.METHODSWe analyzed longitudinal biomarker and cognitive change rates from the Alzheimer's Disease Neuroimaging Initiative (N = 141) and Anti-Amyloid Treatment in Asymptomatic Alzheimer's (A4) and Longitudinal Evaluation of Amyloid Risk and Neurodegeneration (LEARN) (N = 151), estimated using linear mixed models. Using linear models, we tested biomarker changes as predictors of cognitive changes, comparing predictive strengths across biomarkers using bootstrapping.RESULTSTau-PET, plasma p-tau217, and cortical thickness changes accurately tracked change rates in Mini-Mental State Examination, Alzheimer's Disease Assessment Scale-Cognitive Subscale 13-item version, Clinical Dementia Rating-Sum of Boxes, and Preclinial Alzheimer Cognitive Composite scores. In contrast, amyloid-PET change rates were not linked to cognitive changes.DISCUSSIONPlasma p-tau217 offers a cost-effective AD-specific alternative to tau-PET and could potentially be implemented for monitoring cognitive changes in AD trials, while amyloid-PET lacks utility. Cortical thickness changes accurately track cognitive changes but may be confounded by pseudo-atrophy in anti-Aβ treatments.
000281802 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000281802 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x1
000281802 588__ $$aDataset connected to CrossRef, Journals: pub.dzne.de
000281802 7001_ $$aSteward, Anna$$b1
000281802 7001_ $$aDewenter, Anna$$b2
000281802 7001_ $$aDehsarvi, Amir$$b3
000281802 7001_ $$aZhu, Zeyu$$b4
000281802 7001_ $$aRoemer-Cassiano, Sebastian N$$b5
000281802 7001_ $$aFrontzkowski, Lukas$$b6
000281802 7001_ $$aHirsch, Fabian$$b7
000281802 7001_ $$0P:(DE-2719)9000852$$aPalleis, Carla$$b8$$udzne
000281802 7001_ $$0P:(DE-2719)2811373$$aHöglinger, Günter$$b9$$udzne
000281802 7001_ $$0P:(DE-2719)9001539$$aBrendel, Matthias$$b10$$udzne
000281802 7001_ $$00000-0001-9736-2283$$aFranzmeier, Nicolai$$b11
000281802 773__ $$0PERI:(DE-600)2201940-6$$a10.1002/alz.70783$$gVol. 21, no. 10, p. e70783$$n10$$pe70783$$tAlzheimer's and dementia$$v21$$x1552-5260$$y2025
000281802 8564_ $$uhttps://pub.dzne.de/record/281802/files/DZNE-2025-01188%20SUP1.docx
000281802 8564_ $$uhttps://pub.dzne.de/record/281802/files/DZNE-2025-01188%20SUP2.pdf
000281802 8564_ $$uhttps://pub.dzne.de/record/281802/files/DZNE-2025-01188.pdf$$yOpenAccess
000281802 8564_ $$uhttps://pub.dzne.de/record/281802/files/DZNE-2025-01188%20SUP1.doc
000281802 8564_ $$uhttps://pub.dzne.de/record/281802/files/DZNE-2025-01188%20SUP1.odt
000281802 8564_ $$uhttps://pub.dzne.de/record/281802/files/DZNE-2025-01188%20SUP1.pdf
000281802 8564_ $$uhttps://pub.dzne.de/record/281802/files/DZNE-2025-01188%20SUP2.pdf?subformat=pdfa$$xpdfa
000281802 8564_ $$uhttps://pub.dzne.de/record/281802/files/DZNE-2025-01188.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000281802 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000852$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b8$$kDZNE
000281802 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811373$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b9$$kDZNE
000281802 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001539$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b10$$kDZNE
000281802 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000281802 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x1
000281802 9141_ $$y2025
000281802 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-06
000281802 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-06
000281802 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000281802 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bALZHEIMERS DEMENT : 2022$$d2025-01-06
000281802 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2025-01-06$$wger
000281802 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-06
000281802 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bALZHEIMERS DEMENT : 2022$$d2025-01-06
000281802 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-06
000281802 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000281802 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-06
000281802 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-01-06
000281802 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-06
000281802 9201_ $$0I:(DE-2719)1111015$$kClinical Research (Munich)$$lClinical Research (Munich)$$x0
000281802 9201_ $$0I:(DE-2719)1110007$$kAG Haass$$lMolecular Neurodegeneration$$x1
000281802 980__ $$ajournal
000281802 980__ $$aVDB
000281802 980__ $$aUNRESTRICTED
000281802 980__ $$aI:(DE-2719)1111015
000281802 980__ $$aI:(DE-2719)1110007
000281802 9801_ $$aFullTexts